Stockholm-Uppsala Life Science AB

Latest report shows Stockholm-Uppsala maintaining position as leading international life sciences hub

Pressmeddelande   •   Okt 08, 2012 15:02 CEST

Major Euros 7 billion investment underway to further strengthen life science leadership

A new report published today by Stockholm-Uppsala Life Science shows that the region maintained its position as one of the leading international life science clusters with over 600 companies employing some 23,400 and generating a combined turnover of SEK 177 billion. (Euros 21 billion). Furthermore, the report notes that despite recent redundancies at AstraZeneca, the future for the region is positive with ambitious plans already underway. These comprise major public-private investments in research funding, research and physical infrastructure, including a new university hospital, totaling over SEK 60 billion (Euros 7 billion). These investments aim at supporting not only existing companies, but also stimulating a new generation and thus ensuring the region remains a truly global life sciences cluster.

Stockholm-Uppsala Life Sciences CEO, Ola Björkman commented: “Originally built around the industrial strength of Pharmacia and Astra interacting with the research knowhow at universities including Karolinska Institutet and Uppsala University, the Stockholm-Uppsala region has, I believe, now reached an important new stage in its development. The Astra Zeneca downsizing has shown we are not immune to global trends, but on the other hand the decision of numerous companies such as Kemwell and Cepheid to expand their footprint demonstrates that we continue to be able to offer an attractive and stable business environment. It is especially pleasing to see that the new investments have the backing of all stakeholders, including government. The government’s $320 million investment over the next 4 years in life science, including funds for SciLifeLab, will create a new foundation for translational protein science and in turn stimulate company creation.”

Copies of the report are available to download at www.suls.se

For more information please contact: CEO, Ola Björkman, Stockholm-Uppsala Life Science +46 70 245 74 97

Stockholm-Uppsala is the region where business and research thrive! Our region is a hot-bed of creative cross-disciplinary collaboration and, together, we are building international businesses and delivering real research breakthroughs that will help solve the world’s health problems. We’re open-minded and productive. Our state-of-the-art infrastructure and talented scientists provide all the services and support you’ll need. www.suls.se